



UNITED STATES PATENT AND TRADEMARK OFFICE

23 AUG 2007

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

NOVARTIS VACCINES AND DIAGNOSTICS INC.
CORPORATE INTELLECTUAL PROPERTY R338
P.O. BOX 8097
Emeryville CA 94662-8097

In re Application of	:	
MACKICHAN, Mary Lee, et al.	:	
Application No.: 10/530,000	:	DECISION
PCT No.: PCT/US2003/031320	:	
Int. Filing Date: 01 October 2003	:	ON PETITION UNDER
Priority Date: 01 October 2002	:	
Docket No.: CHIR0006-101	:	37 CFR 1.137(b)
For: ANTI-CANCER AND ... FOR USING	:	
SAME	:	

Applicants' renewed Petition Under 37 CFR 1.137(b), filed in the above-captioned application on 19 June 2007 is **GRANTED**.

Applicants have indicated that the entire delay was unintentional. This is construed to mean that the entire delay in filing the proper response from the abandonment until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. If this is not a correct understanding, applicants must notify the Office immediately. The petition fee has been submitted. Applicants have now supplied a declaration in compliance with 37 CFR 1.497(a)-(b). A terminal disclaimer is not required as the application was filed on or after 08 June 1995. Accordingly, all requirements under 37 CFR 1.137(b) have been satisfied.

This application is being forwarded to the National Stage Processing Branch of the Office of PCT Operations for continued processing in accordance with this decision. The application has a 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) date of 19 June 2007.

Erin P. Thomson

Erin P. Thomson
Attorney Advisor
PCT Legal Administration

Telephone: 571-272-3292
Facsimile: 571-273-0459